Skip to main content

Table 4 Adverse events

From: Caspofungin Use in Daily Clinical Practice for Treatment of Invasive Aspergillosis: Results of a Prospective Observational Registry

Type of Adverse Events

Clinical Adverse Events*

N = 103

n (%)

Laboratory Adverse Events**

N = 103

n (%)

Any adverse events

4 (3.9)

8 (7.8)

Serious adverse events

3 (2.9)

1 (0.9)

Serious adverse events leading to discontinuation

2 (1.9)

1 (0.9)

  1. * Clinical adverse events include: bronchopneumonia; skin reaction; respiratory failure; and abdominal pain
  2. **Laboratory adverse events include: increase in aspartate aminotransferase, alanine aminotransferase, blood alkaline phosphatase, blood bilirubin, gamma glutamyltransferase; leukopenia; hyperbilirubinemia; and hypokalemia.